for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Orion Corp

ORNBV.HE

Latest Trade

40.32EUR

Change

-0.21(-0.52%)

Volume

326,418

Today's Range

40.02

 - 

40.56

52 Week Range

28.19

 - 

40.96

As of on the Helsinki Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
40.53
Open
40.52
Volume
326,418
3M AVG Volume
7.11
Today's High
40.56
Today's Low
40.02
52 Week High
40.96
52 Week Low
28.19
Shares Out (MIL)
140.49
Market Cap (MIL)
5,670.59
Forward P/E
28.29
Dividend (Yield %)
--

Next Event

Q4 2019 Orion Corp Earnings Release

Latest Developments

More

Orion Group Q3 Operating Profit Up At EUR 90.7 Mln

Orion To Withdraw Melatoniini Orion Spray

Oriola And Orion Renew Their Distribution Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Orion Corp

Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, and the Diagnostics business segment develops, manufactures and markets diagnostic tests. The Company’s business comprises two main divisions: Proprietary Products and Specialty Products. Its Proprietary Products consist of patented prescription products in three therapy areas: central nervous system diseases, oncology and critical care, and Easyhaler pulmonary drugs. The Company’s Specialty Products, which include the provision of generic prescription drugs and self-care products for basic healthcare. In addition the Company also produces veterinary medicines for pets and production animals.

Industry

Biotechnology & Drugs

Contact Info

Orionintie 1A

+358.10.4261

http://www.orion.fi

Executive Leadership

Heikki Westerlund

Independent Chairman of the Board

Timo Lappalainen

President, Chief Executive Officer, Chairman of the Executive Management Board

Timo Maasilta

Independent Vice Chairman of the Board

Jari Karlson

Chief Financial Officer; Senior Vice President, Animal Health; Member of the Executive Management Board

Satu Ahomaki

Senior Vice President, Commercial Operations; Member of the Executive Management Board

Key Stats

4.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

1.1K

2017

1.1K

2018

1.0K

2019(E)

1.0K
EPS (EUR)

2016

1.770

2017

1.610

2018

1.400

2019(E)

1.424
Price To Earnings (TTM)
27.11
Price To Sales (TTM)
5.46
Price To Book (MRQ)
7.95
Price To Cash Flow (TTM)
21.71
Total Debt To Equity (MRQ)
1.15
LT Debt To Equity (MRQ)
0.72
Return on Investment (TTM)
26.59
Return on Equity (TTM)
20.68

Latest News

Latest News

BRIEF-Orion: Completion Of Rolling Submission Of NDA For Darolutamide To FDA

* ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR DAROLUTAMIDE TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)

BRIEF-Orion Oyj to sell its Orion Diagnostica division

* REG-ORION TO SELL ITS ORION DIAGNOSTICA DIVISION - DUE TO THE TRANSACTION ORION UPDATES ITS OUTLOOK

BRIEF-Orion Updates Primary Completion Date Of Phase III To September 2018

* STATUS UPDATE OF THE PHASE III ARAMIS CLINICAL TRIAL WITH DAROLUTAMIDE IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

BRIEF-Orion: Positive Conclusions For Salmeterol-Fluticasone Easyhaler Combination Under EU's Decentralized Procedures

* ORION HAS RECEIVED POSITIVE CONCLUSIONS FOR THE SALMETEROL-FLUTICASONE EASYHALER® COMBINATION UNDER THE EU'S DECENTRALIZED PROCEDURES

BRIEF-Orion Conducts Personnel Reduction of 17 Positions

* 17 PERSONS OF COMPANY'S PERSONNEL WILL BE GIVEN A NOTICE.

BRIEF-Orion Q4 EBIT Above Expectations At EUR 73.1 Million

* ESTIMATES THAT IN 2018 NET SALES WILL BE AT SAME LEVEL OR SLIGHTLY LOWER THAN IN 2017

BRIEF-Orion To Investigate Possible Sale Of Orion Diagnostica

* REG-ORION TO INVESTIGATE POSSIBLE SALE OF ORION DIAGNOSTICA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Iraq, Orion sign deal to process gas from giant oilfield

Iraq agreed a deal with U.S. energy company Orion on Monday to process natural gas extracted at its giant Nahr Bin Omar oilfield.

IRAQ SIGNS AGREEMENT WITH U.S. FIRM ORION TO PROCESS GAS FROM NAHR BIN OMAR OILFIELD - IRAQI OIL MINISTRY

IRAQ SIGNS AGREEMENT WITH U.S. FIRM ORION TO PROCESS GAS FROM NAHR BIN OMAR OILFIELD - IRAQI OIL MINISTRY

BRIEF-Orion To Launch Negotiations That May Result In Personnel Reductions

* COMPANY WILL LAUNCH CO-OPERATION NEGOTIATIONS IN LABORATORY OPERATIONS

BRIEF-Orion Q3 EBIT EUR 56.4 million, misses expectations

* Q3 SALES EUR 252.7 MILLION (REUTERS POLL EUR 266 MILLION)

BRIEF-Revival Gold announces strategic relationship with Orion Mine Finance

* Revival Gold Inc closes $9 million private placement and announces strategic relationship with Orion Mine Finance

BRIEF-Shareholders of Osisko Gold Royalties Ltd approve Orion transaction

* Osisko Gold Royalties Ltd - shareholders have approved at 99.6% issuance of shares required to complete acquisition of Orion portfolio

BRIEF-Orion Oyj Q4 EBIT at EUR 58.7 million, above estimates

* Q4 sales 279.9 million euros ($298.18 million) versus 273 million euros seen in Reuters poll

BRIEF-Government Of Singapore buys 5.0 pct stake in Orion

* Says Government Of Singapore has acquired 302,186 shares of the company, increasing its stake in the cpmpany up to 5.0 percent from 0 percent

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up